Format

Send to

Choose Destination
Blood. 2017 Jan 26;129(4):497-508. doi: 10.1182/blood-2016-05-714493. Epub 2016 Oct 18.

The EMT regulator ZEB2 is a novel dependency of human and murine acute myeloid leukemia.

Li H1,2,3, Mar BG4,5, Zhang H1,2,3, Puram RV4,5, Vazquez F5, Weir BA5, Hahn WC4,5, Ebert B4,5, Pellman D1,2,3.

Author information

1
Howard Hughes Medical Institute, Chevy Chase, MD.
2
Department of Pediatric Oncology, Dana-Farber Cancer Institute and Pediatric Hematology/Oncology, Boston Children's Hospital, Boston, MA.
3
Department of Cell Biology, Harvard Medical School, Boston, MA.
4
Division of Hematology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; and.
5
Broad Institute of MIT and Harvard, Cambridge, MA.

Abstract

Acute myeloid leukemia (AML) is a heterogeneous disease with complex molecular pathophysiology. To systematically characterize AML's genetic dependencies, we conducted genome-scale short hairpin RNA screens in 17 AML cell lines and analyzed dependencies relative to parallel screens in 199 cell lines of other cancer types. We identified 353 genes specifically required for AML cell proliferation. To validate the in vivo relevance of genetic dependencies observed in human cell lines, we performed a secondary screen in a syngeneic murine AML model driven by the MLL-AF9 oncogenic fusion protein. Integrating the results of these interference RNA screens and additional gene expression data, we identified the transcription factor ZEB2 as a novel AML dependency. ZEB2 depletion impaired the proliferation of both human and mouse AML cells and resulted in aberrant differentiation of human AML cells. Mechanistically, we showed that ZEB2 transcriptionally represses genes that regulate myeloid differentiation, including genes involved in cell adhesion and migration. In addition, we found that epigenetic silencing of the miR-200 family microRNAs affects ZEB2 expression. Our results extend the role of ZEB2 beyond regulating epithelial-mesenchymal transition (EMT) and establish ZEB2 as a novel regulator of AML proliferation and differentiation.

PMID:
27756750
PMCID:
PMC5270388
DOI:
10.1182/blood-2016-05-714493
[Indexed for MEDLINE]
Free PMC Article

Publication types, MeSH terms, Substances, Grant support

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center